cGAS

cGAS is a cytosolic DNA sensor that detects genomic instability and mitochondrial damage and then activates sting to drive an IFN-I response. Its core mechanism is DNA binding, with recent work showing that zinc ions can enhance cGAS-DNA binding and amplify cGAS-STING signaling, while in situ-formed DNA networks can act as potent agonists. In tumors, methionine depletion can reduce methylation, promote cGAS dissociation from chromatin, and thereby facilitate STING pathway activation. The protein is also implicated in Parkinson’s disease pathogenesis, where cGAS-STING signaling is being explored as a disease-modifying axis. Overall, cGAS sits at the intersection of innate immune sensing, genomic instability, mitochondrial stress, and immunotherapy, with multiple recent studies leveraging its activation for therapeutic benefit.

Cancer / Immunotherapy

  • A 2026 Biomaterials study used a nanosystem to target genomic instability and mitochondrial damage to stimulate the STING pathway for synergistic immunotherapy in advanced prostate cancer, consistent with cGAS sensing of damaged DNA and mitochondrial dysfunction (PMID:41628534).
  • In the same study, Zn2+ enhanced cGAS-DNA binding and amplified cGAS-STING signaling, highlighting a metal-ion-dependent boost to innate immune activation (PMID:41628534).
  • Methionine-depleting engineered probiotics promoted PD-L1 antibody immunotherapy by activating the STING pathway; methionine depletion reduced methylation in tumor cells and facilitated dissociation of cGAS from chromatin (PMID:41604978).
  • Intracellular DNA network assembly triggered by microRNA and telomerase produced an in situ DNA network that acted as a potent cGAS agonist for imaging-guided STING hyperactivation (PMID:41724120).

Neurodegeneration

  • cGAS-STING activation has been reviewed as a mechanistic contributor to Parkinson’s disease pathogenesis and a potential disease-modifying therapeutic target (PMID:41500413).
  • The Parkinson’s disease literature emphasizes cGAS as a cytosolic DNA sensor linking mitochondrial damage to inflammatory signaling through STING activation (PMID:41500413).
  • Disease-modifying strategies are being discussed around dampening or redirecting cGAS-STING signaling in Parkinson’s disease (PMID:41500413).